An enhanced EBNA1 variant with reduced IR3 domain for long-term episomal maintenance and transgene expression of oriP-based plasmids in human cells

Gene Therapy

Volumn 5, Issue 10, 1998, Pages 1389-1399

  Wendelburg, B J ^a   Vos, J M H ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

EBNA1; Episomal maintenance; Epstein Barr virus; Gene therapy; oriP

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN; ISOPROTEIN; PLASMID DNA; TRANSACTIVATOR PROTEIN;

ARTICLE; ASSAY; B LYMPHOCYTE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DNA REPLICATION; DNA TRANSFECTION; EPISOME; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PLASMID; PRIORITY JOURNAL; RAJI CELL; REPORTER GENE; TRANSGENE;

EID: 0031728485     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300736     Document Type: Article

References (38)

1. Bussen P et al. Epstein-Barr virus-containing epithelial cells from nasopharyngeal carcinoma produce interleukin 1 alpha. Proc Natl Acad Sci USA 1987; ; 84: 6262-6266.
2. Labrecque LG et al. Epstein-Barr virus in epithelial cell tumors: a Breast Cancer Study. Cancer Res 1995; ; 55: 39-45.
3. Harn HJ et al. Epstein-Barr virus-associated typical gastric carcinoma detected by in situ hybridization and polymerase chain reaction. J Clin Gastroenterol 1995; ; 20: 253-254.
4. Hampar B et al. Replication of the resident repressed EpsteinBarr virus genome during the early S phase (S-l period) of nonproducer Raji cells. Proc Natl Acad Sci USA 1974; ; 71: 631-635.
5. Adam A. Replication of latent Epstein-Barr virus genomes in Raji cells. J Virol 1987; ; 61: 1743-1746.
6. Yates JL, Guan N. Epstein-Barr virus-derived plasmids replicate only once per cell cycle and are not amplified after entry into cells. J Virol 1991; ; 65: 483-488.
7. Vos J-MH (ed). Herpesviruses as genetic vectors. Viruses in Human Gene Therapy. Carolina Academic Press and Chapman & Hall: Durham NC, London, 1995, pp 109-140.
8. Banerjee S, Livanos L, Vos J-MH. Therapeutic gene delivery in human B-lymphoblastoid cells by engineered non-transforming Epstein-Barr virus. Nature Med 1995; ; 1: 1303-1308.
9. Wang F et al. Tap-1 and Tap-2 gene therapy selectively restores conformationally dependent HLA class I expression in type I diabetic cells. Hum Gene Ther 1995; ; 6: 1005-1017.
10. Sun T-Q, Livanos E, Vos J-MH. Engineering a mini-herpesvirus as a general strategy to transduce up to 180 kb of functional self-replicating human mini-chromosomes. Gene Therapy 1996; ; 3: 1081-1088.
11. Yates JL. Epstein-Ban virus DNA replication. In: Pamphilis ML (ed). DNA Replication in Eukaryonc Cells, 31 edn. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1996; pp 751-773.
12. Gahn TA, Schildkraut CL. The Epstein-Barr virus origin of plasmid replication, oriP, contains both the initiation and termination sites of DNA replication. Cell 1989; ; 58: 527-535.
13. Wysokenski DA, Yates JL. Multiple EBNAl-binding sites are required to form an EBNA1-dependent enhancer and to activate a minimal replicative origin within oriP of Epstein-Barr virus. J Virol 1989; ; 63: 2657-2666.
14. Harrison S, Fisenne K, Hearing J. Sequence requirements of the Epstein-Barr virus latent origin of DNA replication. J Virol 1994; ; 68: 1913-1925.
15. Frappier L, O'Donnell M. Epstein-Barr nuclear antigen 1 mediates a DNA loop within the latent replication origin of Epstein-Barr virus. Proc Natl Acad Sci USA 1991; 88: 10875-10879.
16. Su W et al. DNA looping between the origin of replication of Epstein-Barr virus and its enhancer site: stabilization of an origin complex with Epstein-Barr nuclear antigen 1. Proc Natl Acad Sci USA 1991; 88: 10870-10874.
17. Middelton T, Sugden B. EBNA1 can link the enhancer element to the initiator element of the Epstein-Barr virus plasmid origin of DNA replication. J Virol 1992; 66: 489-495.
18. Yates JL, Camiolo SM. Dissection of DNA replication and enhancer activation functions of Epstein-Barr virus nuclear antigen 1. Cancer Cells 1988; 6: 197-205.
19. Ambinder RF et al. Functional domains of Epstein-Barr virus nuclear antigen EBNA-1. J Virol 1991; 65: 1466-1478.
20. Inoue N et al. The domain of Epstein-Barr virus nuclear antigen 1 essential for binding to oriP region has a sequence fitted for the hypothetical basic-helix-loop-helix structure. Virology 1991; 182: 84-93.
21. Chen M-R, Middeldorp JM, Hayward SD. Separation of the complex DNA binding domain of EBNA-1 into DNA recognition and dimerization subdomains of novel structure. J Virol 1993; 67: 4875-1885.
22. Goldsmith K, Bendell L, Frappler L. Identification of EBNA1 amino acid sequences required for the interaction of the functional elements of the Epstein-Barr virus latent origin of DNA replication. J Virol 1993; 67: 3418-3426.
23. Mackey D, Middelton T, Sugden B. Multiple regions within EBNA1 can link DNAs. J Virol 1995; 69: 6199-6208.
24. Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985; 313: 812-815.
25. Klein G. Epstein-Barr virus strategy in normal and neoplastic cells. Cell 1994; 77: 791-793.
26. Levitskaya J et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995; 375: 685-688.
27. Hennessy K et al. Simple repeat array in Epstein-Barr virus DNA encodes part of the Epstein-Barr nuclear antigen. Science 1983; 220: 1396-1398.
28. Ben-Bassat H et al. Establishment in continuous culture of a new type of lymphocyte from a 'Burkitt-like' malignant lymphoma (line D.G.-75). Int J Cancer 1977; 19: 27-33.
29. Palmer T, Thompson AR, Miller AD. Production of human fac tor IX in animals by genetically modified skin fibroblasts: potential therapy for hemophilia B. Blood 1989; 73: 438-445.
30. Scharfmann R, Axelrod JH, Verrna IM. Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. Proc Natl Acad Sci USA 1991; 88: 4626-4630.
31. Summers DK. The kinetic of plasmid loss. Trends Biotechnol 1991; 9: 273-278.
32. Barwell JA et al. Overexpression, purification, and crystallization of the DNA binding and dimerization domains of the EpsteinBarr virus nuclear antigen 1. J Biol Chem 1995; 270: 20556-20559.
33. Bochkarev A et al. Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA. Cell 1996; 84: 791-800.
34. Snudden DK et al. Alterations in the structure of the EBV nuclear antigen, EBNA1, in epithelial cell tumors. Oncogene 1995; 10: 1545-1552.
35. Stemas L, Middleton T, Sugden B. The average number of molecules of Epstein-Barr nuclear antigen 1 per cell does not correlate with the average number of Epstein-Barr virus (EBV) DNA molecules per cell among different clones of EBV-immortalized cells. J Virol 1990; 64: 2407-2410.
36. Licht T et al. In vivo drug-selectable genes: a new concept in gene therapy. Stem Cells 1997; 15: 104-111.
37. Sun T-Q, Fenstermacher D, Vos J-MH. Human artificial episomal chromosomes for cloning large DNA in human cells. Nat Genet 1994; 8: 33-11.
38. 10Techniques 1989; 7: 576-579.